RAS Mutation Identifies a Poor Prognostic Molecular Subtype of Therapy-Related Myeloid Neoplasm
Blood Adv
.
2025 May 22:bloodadvances.2025016374.
doi: 10.1182/bloodadvances.2025016374.
Online ahead of print.
Authors
Chung Hoow Kok
1
,
Aref Al-Kali
2
,
Daniel Thomas
3
,
Rong He
2
,
Monika M Kutyna
4
,
Hassan B Alkhateeb
2
,
Kelly Lim
5
,
Antoine N Saliba
2
,
Carla Toop
6
,
Aasiya Matin
2
,
Hamish S Scott
7
,
Naseema Gangat
2
,
Anna L Brown
1
,
Abhishek A Mangaonkar
2
,
Christopher N Hahn
1
,
Kebede Begna
2
,
Kevin Hung
8
,
Patricia T Greipp
2
,
William J Hogan
9
,
Mrinal M Patnaik
2
,
Mithun Vinod Shah
2
,
Devendra K Hiwase
10
Affiliations
1
SA Pathology, Adelaide, Australia.
2
Mayo Clinic, Rochester, Minnesota, United States.
3
The University of Adelaide, Adelaide, Australia.
4
South Australian Health and Medical Research Institute, Adelaide, Australia.
5
University of Adelaide, Adelaide, Australia.
6
Central Adelaide Local Health Network, Adelaide, Australia.
7
Centre for Cancer Biology, an Alliance between SA pathology and the University of South Australia, Adelaide, Australia.
8
Royal Adelaide Hospital, Adelaide, Australia.
9
Mayo Medical Center, Rochester, Minnesota, United States.
10
Royal Adelaide Hospital, Central Adelaide Local Health Network, Adelaide, Australia.
PMID:
40402688
DOI:
10.1182/bloodadvances.2025016374
No abstract available